Cancer Drugs in Dogs Highlight Specialty Pharmacy Week in Review

Article

Top stories of the week on Specialty Pharmacy Times from June 22-26.

[<a href="//storify.com/pharmacytimes/cancer-drugs-in-dogs-highlight-specialty-pharmacy-" target="_blank">View the story "Cancer Drugs in Dogs Highlight Specialty Pharmacy Week in Review" on Storify</a>]

Related Videos
Credit: Adobe Stock - Tierney
https://www.youtube.com/watch?v=Q-WCvWaAcC8
Yaruniv-Studio - stock.adobe.com
Technician- © pharmacytimes
Pills on a background of a one hundred American dollar bill | Image credit: Cagkan - stock.adobe.com
Credit: Cagkan - stock.adobe.com
Specialty pharmacy illustration | Image credit: BillionPhotos.com - stock.adobe.com
Biosimilars | Image credit: lexiconimages - stock.adobe.com
Related Content

Artificial Intelligence Is Revolutionizing Controlled Substance Diversion Detection

September 14th 2023

Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

September 8th 2023

Phase 3 Trial Shows Combined Nivolumab, Ipilimumab Treatment Improved OS in Patients With mNSCLC

September 12th 2023

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

May 19th 2023

FDA Approves IND for CT7439, a Novel CDK12/13 Inhibitor to Treat Multiple Types of Advanced Solid Tumors

September 11th 2023

Inhibiting PI3K/mTOR, SIRT2 Pathways May Be Effective in Treating Aggressive AML

September 11th 2023

Artificial Intelligence Is Revolutionizing Controlled Substance Diversion Detection

September 14th 2023

Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

September 8th 2023

Phase 3 Trial Shows Combined Nivolumab, Ipilimumab Treatment Improved OS in Patients With mNSCLC

September 12th 2023

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

May 19th 2023

FDA Approves IND for CT7439, a Novel CDK12/13 Inhibitor to Treat Multiple Types of Advanced Solid Tumors

September 11th 2023

Inhibiting PI3K/mTOR, SIRT2 Pathways May Be Effective in Treating Aggressive AML

September 11th 2023

Artificial Intelligence Is Revolutionizing Controlled Substance Diversion Detection

September 14th 2023

Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

September 8th 2023

Phase 3 Trial Shows Combined Nivolumab, Ipilimumab Treatment Improved OS in Patients With mNSCLC

September 12th 2023

Pharmacy Focus: Psychedelic Pharmacy - Managing Potential Adverse Effects With Psychedelic Medicines

May 19th 2023

FDA Approves IND for CT7439, a Novel CDK12/13 Inhibitor to Treat Multiple Types of Advanced Solid Tumors

September 11th 2023

Inhibiting PI3K/mTOR, SIRT2 Pathways May Be Effective in Treating Aggressive AML

September 11th 2023
© 2023 MJH Life Sciences

All rights reserved.